<DOC>
	<DOC>NCT02368743</DOC>
	<brief_summary>This national, observational and multicentre study aims at establishing a picture of real clinical practices management among patients treated with Pentasa®, according to the current therapeutic strategy in ulcerative proctitis. This study should be able to provide data on patients' health related quality of life, compliance and efficacy in real clinical practice.</brief_summary>
	<brief_title>QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)</brief_title>
	<detailed_description />
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patient aged 18 years or older. Patient suffering from mild to moderate active proctitis (MAYO score ≥ 3 and ≤ 10) at inclusion based on clinical and endoscopic findings within one month before study inclusion Patient with evidence of endoscopic active proctitis (Montreal classification E1 defined by an involvement limited to the rectum that is, proximal extent of inflammation is distal to the rectosigmoid junction) within one month before study inclusion. Patient for whom the investigator has decided to start during the inclusion visit a treatment of the current flare with Pentasa® to induce a remission. Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form. Patient included in an interventional study assessing treatment for active proctitis Patient with left sided, sigmoiditis or pancolitis. Patient with severe proctitis (MAYO score ≥ 11 at inclusion). Patient previously treated with biologics. Patient treated with immunosuppressive within 1 month before study inclusion. Patient treated with corticosteroids within 2 weeks before study inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>